176 related articles for article (PubMed ID: 24923537)
1. Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.
Bemer MJ; Risler LJ; Phillips BR; Wang J; Storer BE; Sandmaier BM; Duan H; Raccor BS; Boeckh MJ; McCune JS
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1544-52. PubMed ID: 24923537
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.
Li H; Mager DE; Sandmaier BM; Storer BE; Boeckh MJ; Bemer MJ; Phillips BR; Risler LJ; McCune JS
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1121-9. PubMed ID: 24727337
[TBL] [Abstract][Full Text] [Related]
3. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
[TBL] [Abstract][Full Text] [Related]
6. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells.
Glander P; Braun KP; Hambach P; Bauer S; Mai I; Roots I; Waiser J; Fritsche L; Neumayer HH; Budde K
Clin Biochem; 2001 Oct; 34(7):543-9. PubMed ID: 11738390
[TBL] [Abstract][Full Text] [Related]
7. Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.
McCune JS; Storer B; Thomas S; McKiernan J; Gupta R; Sandmaier BM
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1802-1807. PubMed ID: 29656138
[TBL] [Abstract][Full Text] [Related]
8. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.
Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA
J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509
[TBL] [Abstract][Full Text] [Related]
9. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients.
Neuberger M; Sommerer C; Böhnisch S; Metzendorf N; Mehrabi A; Stremmel W; Gotthardt D; Zeier M; Weiss KH; Rupp C
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):543-550. PubMed ID: 31924555
[TBL] [Abstract][Full Text] [Related]
10. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
11. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
12. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
13. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
Vethe NT; Bergan S
Ther Drug Monit; 2006 Oct; 28(5):608-13. PubMed ID: 17038874
[TBL] [Abstract][Full Text] [Related]
14. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
Rath T; Küpper M
Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.
Ueda Oshima M; Storer BE; Qiu H; Chauncey T; Asch J; Boyer MW; Giaccone L; Flowers M; Mielcarek M; Storb R; Maloney DG; Sandmaier BM
Transplant Cell Ther; 2021 Feb; 27(2):163.e1-163.e7. PubMed ID: 33830025
[TBL] [Abstract][Full Text] [Related]
17. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
[TBL] [Abstract][Full Text] [Related]
18. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
20. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
